You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

IQUIX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Iquix patents expire, and when can generic versions of Iquix launch?

Iquix is a drug marketed by Santen and is included in one NDA.

The generic ingredient in IQUIX is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Iquix

A generic version of IQUIX was approved as levofloxacin by RISING on December 20th, 2010.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for IQUIX?
  • What are the global sales for IQUIX?
  • What is Average Wholesale Price for IQUIX?
Summary for IQUIX
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 98
Patent Applications: 5,337
DailyMed Link:IQUIX at DailyMed
Drug patent expirations by year for IQUIX

US Patents and Regulatory Information for IQUIX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Santen IQUIX levofloxacin SOLUTION/DROPS;OPHTHALMIC 021571-001 Mar 1, 2004 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for IQUIX

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Chiesi Farmaceutici S.p.A Quinsair levofloxacin EMEA/H/C/002789
Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Authorised no no no 2015-03-25
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for IQUIX

See the table below for patents covering IQUIX around the world.

Country Patent Number Title Estimated Expiration
Japan S6287577 OPTICALLY ACTIVE 3-METHYLBENZOXAZINE DERIVATIVE AND PRODUCTION THEREOF ⤷  Sign Up
Yugoslavia 186788 ⤷  Sign Up
Greece 861625 OPTICALLY ACTIVE PYRIDOBENZOXAZINES DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF ⤷  Sign Up
South Africa 8604518 ⤷  Sign Up
Denmark 641688 ⤷  Sign Up
Slovenia 8811867 OPTICALLY ACTIVE DERIVATIVE OF BENZOXAZINE ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for IQUIX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0206283 SPC/GB97/085 United Kingdom ⤷  Sign Up PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
0206283 98C0041 Belgium ⤷  Sign Up PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
0206283 C980016 Netherlands ⤷  Sign Up PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.